Search

Novo Nordisk A-S (Class B)

Fermé

341.35 -0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

340.8

Max

343.3

Chiffres clés

By Trading Economics

Revenu

-2.5B

27B

Ventes

-1.2B

77B

P/E

Moyenne du Secteur

14.432

37.461

BPA

5.96

Rendement du dividende

3.4

Marge bénéficiaire

34.484

Employés

78,387

EBITDA

44B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+9.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

3.40%

2.33%

Prochains Résultats

5 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

138B

1.5T

Ouverture précédente

341.63

Clôture précédente

341.35

Novo Nordisk A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 oct. 2025, 10:26 UTC

Principaux Mouvements du Marché

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17 oct. 2025, 10:25 UTC

Principaux Mouvements du Marché

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct. 2025, 15:36 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct. 2025, 13:27 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9 oct. 2025, 10:49 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1 oct. 2025, 08:54 UTC

Principaux Mouvements du Marché

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22 oct. 2025, 10:45 UTC

Résultats

AI Stocks Aren't the Only Market Play. How -2-

22 oct. 2025, 10:45 UTC

Résultats

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17 oct. 2025, 10:10 UTC

Principaux Mouvements du Marché

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct. 2025, 12:33 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct. 2025, 12:32 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10 oct. 2025, 16:19 UTC

Acquisitions, Fusions, Rachats

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 oct. 2025, 13:03 UTC

Market Talk
Acquisitions, Fusions, Rachats

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9 oct. 2025, 15:17 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9 oct. 2025, 11:31 UTC

Acquisitions, Fusions, Rachats

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9 oct. 2025, 10:34 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9 oct. 2025, 10:07 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9 oct. 2025, 10:05 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9 oct. 2025, 10:04 UTC

Acquisitions, Fusions, Rachats

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9 oct. 2025, 10:03 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9 oct. 2025, 10:01 UTC

Acquisitions, Fusions, Rachats

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7 oct. 2025, 09:15 UTC

Market Talk

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1 oct. 2025, 09:05 UTC

Actions en Tendance

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept. 2025, 12:04 UTC

Market Talk

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sept. 2025, 13:43 UTC

Acquisitions, Fusions, Rachats

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sept. 2025, 12:30 UTC

Market Talk

Correction to Novo Nordisk Market Talk

18 sept. 2025, 12:00 UTC

Market Talk

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sept. 2025, 08:55 UTC

Actions en Tendance

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) prévision

Objectif de Prix

By TipRanks

9.53% hausse

Prévisions sur 12 Mois

Moyen 1,162.73 DKK  9.53%

Haut 1,550 DKK

Bas 720 DKK

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

7

Achat

2

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat